TTOO T2 BiosystemsWatchlist
About T2 Biosystems Company
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
CR Group Discloses Sale of 13M T2 Biosystems Shares
T2 Biosystems(TTOO.US) 10% Shareholder Sells US$2.27 Million in Common Stocks
$T2 Biosystems(TTOO.US)$ 10% Shareholder CR Group L.P. sold 13.13 million shares of Common Stocks on Sep 27, 28, 2023 at an average price of $0.173 for a total value of $2.27 million. This transaction
What's Going On With T2 Biosystems Stock Friday?
T2 Biosystems, Inc. (NASDAQ:TTOO) shares are trading higher Friday despite a lack of company-specific news. Here's a look at what's going on: What To Know: T2 Biosystems shares are up more than 20% in
Welcome back to Monthly Buzz!
September started with light volumes. Sellers then returned to the market, giving back the gains made at the end of August. Apple's share price remained weak following its new product launch. As we entered the second half of the month, the Fed announced that it would pause rate hikes in September and maintain the target range for the federal funds rate at 5.25%-5.50%.
Despite this, the hawkish tone o...